T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematopoietic neoplasm resulting from the malignant transformation of T-cell progenitors, and comprises~15% and 25% of pediatric and adult ALL cases, respectively. It is well-established that activating NOTCH1 mutations are the major genetic lesions driving T-ALL in most patients, but efforts to develop targeted therapies against this pathway have produced limited success in decreasing leukemic burden and come with significant clinical side effects. A finer detailed understanding of the genetic and molecular mechanisms underlying T-ALL is required identify patients at increased risk for treatment failure and the development of precision medicine strategies. Generation of genetic models that more accurately reflect the normal developmental history of T-ALL are necessary to identify new avenues for treatment. The DNA methyltransferase enzyme DNMT3A is also recurrently mutated in T-ALL patients, and we show here that inactivation of Dnmt3a combined with Notch1 gain-of-function leads to an aggressive T-ALL in mouse models. Moreover, conditional inactivation of Dnmt3a in mouse hematopoietic cells leads to an accumulation of immature progenitors in the thymus, which are less apoptotic. These data demonstrate that Dnmt3a is required for normal T-cell development, and acts as a T-ALL tumor suppressor.
INTRODUCTION T-cell acute lymphoblastic leukemia (T-ALL) arises from the accumulation of genomic abnormalities that induce aberrant proliferation, increased cell survival, and impaired differentiation of immature T-cell progenitors. Like in many cancers, the mechanisms of T-ALL transformation are similar to those regulating normal developmental processes. Thymocyte development progresses through defined stages of differentiation, beginning with the earliest thymic progenitors (ETPs; Lineagec-Kit+ CD25 − ) and progressing through double-negative 2 (DN2; Lineage-c-Kit+ CD25+) and 3 (DN3; Lineage-c-Kit-CD25+) stages before generating mature T cells. 1 The Notch signaling pathway is fundamental for T-lymphopoiesis, and an absolute requirement for T-cell commitment from lymphoid precursors. 2 Notch1 is a transmembrane receptor that functions as a ligand-activated transcription factor. Ligand binding to Notch1 receptors leads to cleavage catalyzed by the γ-secretase complex, resulting in release of Notch Intracellular Domain (NICD), which translocates to the nucleus 3 to activate transcription of downstream target genes. [4] [5] [6] Demonstrating the close link between T-cell development and oncogenesis, the most prevalent genetic lesions in T-ALL patients are activating mutations of NOTCH1, which occur in over 50% of cases. 7 The oncogenic capacity of activated NOTCH1 is readily demonstrated in murine systems by the rapid development of T-ALL in retroviral-driven NICD bone marrow transplant models. 8 Epigenetic dysfunction has a central role in the pathology of many human cancers. Genome sequencing studies have revealed that the de novo DNA methyltransferase enzyme DNMT3A is one of the most recurrently mutated genes across almost all hematopoietic cancers, 9, 10 including T-lineage neoplasms such as T-ALL 11, 12 and T-cell lymphoma 13 where it is mutated in 10-18% of patients. The mutation spectrum of DNMT3A in T-ALL is different from that seen in myeloid neoplasms, suggesting distinct mechanisms of transformation. [9] [10] [11] 14, 15 In T-ALL, DNMT3A mutations frequently associate with NOTCH1 mutations and predict poor clinical outcomes. 14 Understanding the synergistic activity between dysregulated epigenetics and signaling pathways could highlight windows of therapeutic vulnerability for precision medicine. In this study, we elucidated the role of Dnmt3a in T-cell development and transformation using genetic mouse models.
MATERIALS AND METHODS Mice
Animal procedures were approved by the Institutional Animal Care and Use Committee and conducted in accordance with Washington University School of Medicine institutional guidelines. Mice were C57Bl/6 background, Mx1-Cre:Dnmt3a fl/fl and Mx1-Cre:Dnmt3a fl/fl ;Dnmt3b fl/fl mice have been described. 16 Recombination of floxed alleles was mediated by six intraperitoneal injections (300 μg/mouse) of polyinosinic-polycytidylic acid (pIpC; Sigma, St Louis, MO, USA) in phosphate-buffered salin every other day. The following strains were obtained from the Jackson Laboratory (Bar Harbor, ME, USA)-Lck-CRE (003802), CD8a-CRE (008766), Rosa26 NICD (008159), Rosa26 EYFP (006148) and Nr4a1 KO (006187).
Viral transduction and transplantation
Retroviral transduction of c-Kit-enriched bone marrow (anti-CD117 microbeads; Miltenyi Biotec, Auburn, CA, USA) with NICD in the MSCV-IRES-GFP (MIG) retrovirus 8 was performed as previously described. 17 Recipient mice were transplanted by retro-orbital injection following a split dose of 11.0 Gy of irradiation. For T-ALL rescue, Nr4a1 and Dnmt3a were cloned into MSCV-IRES-mCherry (MIC) to transduce primary GFP+ T-ALL cells. A total of 4 × 10 4 GFP+mCherry+ cells were transplanted into secondary recipients. For secondary transplantations, leukemic cells were transplanted into sublethally irradiated (6.0 Gy) mice. The TtRMPVIR retroviral backbone (Addgene, Cambridge, MA, USA) was modified to place Nr4a1-2A-mCherry under the control of a tetracycline-responsive promoter. Sample size was calculated based on published studies for NICD transduction and transplantation 8, 18 to provide at least 80% power to compare a median survival difference of 25% based on two-sided twosample test for proportions (Po 0.05). NICD transduction and transplantation was performed independently for primary mice five times.
Cell purification and flow cytometry
Single cell suspensions were stained with antibodies at 4 o C and analyzed on FACSAria, LSRFortessa, or LSR II platforms (BD, Franklin Lakes, NJ, USA). Lineage marker cocktail consisted of Gr-1, Mac-1, B220, Ter119, CD4 and CD8a. The following antibody (clones) were used (eBioscience, San Diego, CA, USA or Biolegend, San Diego, CA, USA) -Gr-1 (RB6-8C5), Mac-1 (M1/70), B220 (RA3-6B2), Ter119 (TER119), CD4 (GK1.5), CD8 (53-6.7), CD3 (145-2C11), Sca-1 (D7), c-Kit (2B8), CD150 (TC15-12F12.2), CD48 (HM48-1), CD45.1 (A20), CD45.2 (104), Il7rα (A7R34). Apoptosis analysis was performed with the AnnexinV Apoptosis Detection Kit (eBioscience). To detect TCR (T-cell receptor) rearrangement, genomic DNA was isolated using the PureLink Genomic DNA kit (Invitrogen, Carlsbad, CA, USA) and amplified with the following primers; TCR Vb5 Fwd-CCCAGCAG ATTCTCAGTCCAACAG, TCR Jb2 Rev-TGAGAGCTGTCTCCTACTATCGATT. Real-time PCR was performed with Taqman probes (Applied Biosystems, Foster City, CA, USA).
Cell culture and western blot P12-Ichikawa cells (DSMZ, Braunschweig, Germany) were cultured in RPMI-1640 (Gibco, Carlsbad, CA, USA) supplemented with 10% heat inactivated fetal bovine serum (EMD Millipore, Billerica, MA, USA) and penicillin/streptomycin. All shRNAs expressed in pLKO.1-GFP lentivirus with the following target sequences-DNMT3A#1 (CCCAAGGTCAAGGAGAT TATT), DNMT3A#2 (CCGGCTCTTCTTTGAGTTCTA), DNMT3A#3 (GCCTCAGA GCTATTACCCAAT), DNMT3A#4 (CCAGATGTTCTTCGCTAATAA), DNMT3A#5 (CCACCAGAAGAAGAGAAGAAT), Dnmt3b#1 (CCAGGAGTATTTGAAGATGAT), Dnmt3b#2 (GCTCTGATATTCTAATGCCAA), Dnmt3b#3 (CCCAAGTTGTACCC AGCAATT), Dnmt3b#4 (GCACTTTAATCTGGCTACCTT), Dnmt3b#5 (CAAGAA AGACATCTCAAGATT). For Dnmt3b shRNAs, plasmids were pooled in equimolar ratios, and lentivirus produced using the pooled DNA. OP9-DL1 stromal cells were cultured in α-MEM (Gibco) with 20% fetal bovine serum and penicillin/streptomycin. For T-cell assay, HSCs were isolated, transduced and sorted onto OP9-DL1 cells along with recombinant mFlt3L (5 ng/ml; Miltenyi Biotec) and mIL-7 (1 ng/ml; Miltenyi Biotec). Doxycycline (Sigma) and Cytosporone B (Sigma) was prepared as per manufacturer's instructions. Protein samples were prepared using RIPA Lysis Buffer (Santa Cruz, Dallas, TX, USA). Primary antibodies were used to detect NICD (TA5000078; OriGene, Rockville, MD, USA), DNMT3A (SC-20703; Santa Cruz), NR4A1 (TA314017; OriGene), β-actin (SC-47778; Santa Cruz). Blots were developed using ECL substrate WBKLS010 (EMD Millipore). Chromatin immunoprecipitation with DNMT3A or control IgG antibodies was performed as previously described. 19 ChIP-qPCR reactions were performed using Power SYBR Green Mastermix (Applied Biosystems) on the StepOnePlus Real-Time PCR System (Applied Biosystems) with the following primers: NR4A1 Fwd -AACGTTTGGAGTAGCTGGGA, NR4A1 Rev-AGGAGTTTGAGACCAGCCTG. ACTB ChIP-grade primers were ordered from Diagenode (C17011048; Denville, NJ, USA).
Microarray and RNA-seq RNA was isolated using the NucleoSpin RNA XS kit (Macherey-Nagel, Bethlehem, PA, USA). For microarray analysis, RNA was processed using the Pico Ovation Kit (NuGen, San Carlos, CA, USA) and hybridized to Mouse Gene 2.0 arrays (Affymetrix, Santa Clara, CA, USA). Affymetrix chip data were normalized and analyzed using Transcriptome Analysis Console 2.0 (Affymetrix). For RNA-seq, library preparation was performed with the SMARTer Ultra Low RNA kit (Takara, Mountain View, CA, USA) and sequenced on HiSeq2500 (Illumina, San Diego, CA, USA). RNA-seq reads were aligned to the mouse genome (mm10) with STAR version 2.4.2a. Gene-level transcript counts were then imported into the R/Bioconductor package EdgeR. Genes not expressed in any sample were excluded from further analysis. Differentially expressed genes were filtered for foldchange 42 with false-discovery rate o0.05.
Enhanced representation bisulfite sequencing and analysis eRRBS was performed as previously described. 20 Libraries were prepared from 25 ng of genomic DNA and sequenced on a HiSeq2500 sequencer (Illumina). Low quality sequence were trimmed by using Picard tools, and filtered reads were aligned to mouse genome (mm9) using Bismark version 0.14.5 running Bowtie2 version 2.1.0. CpG methylation was calculated using bismark_methylation_extractor. For identification of DMRs, the genome was split into 100 bp windows with 50 bp sliding step. Highquality windows were defined as containing at least three CpG sites (410 × coverage) in each biological replicate. The significance of DNA methylation difference in each comparison was tested using nonparamedic Wilcoxon singed-rank test followed by Benjamini & Hochberg correction. DMRs were defined as windows with false-discovery rate q-value o 0.05 with averaged DNA methylation difference 425%. Genome annotations were downloaded from the UCSC Genome Browser. Promoters were defined as the 2.5 kb surrounding the TSS (−500 bp/ +2000 bp) of RefSeq genes. Mouse bone marrow superenhancer data were downloaded from dbSUPER data base. Mouse bone marrow H3K27ac ChIPseq peaks (ENCFF061JZQ) was downloaded from ENCODE, the active enhancers were defined as H3K27ac peaks that locating out of gene promoters. For hypergeometric distribution calculation, the probability mass function of hypergeometric distribution is calculated as:
Where N is the number of non-overlapping 150 bp windows (average length of DMRs) in mouse genome, K is the number of non-overlapping 150 bp windows of each genomic features in mouse genome, n is the number of DMRs, and k is the number of DMRs that overlapping to each genomic features. Data have been uploaded to the NCBI Gene Expression Omnibus under accession numbers GSE83769, GSE83755, GSE83759. 
Statistics

RESULTS
Dnmt3a loss-of-function co-operates with Notch1 gain-of-function to accelerate T-ALL We used mouse models to examine genetic co-operation between (Figure 1e ). To exclude the possibility that accelerated leukemogenesis was due to a higher content of T-ALL-initiating cells in the Dnmt3a KO bolus, 1 × 10 3 NICD+ c-Kit+ Sca-1+ cells were isolated 2 days post transduction and transplanted. Latency to T-ALL was again significantly accelerated in a Dnmt3a KO background (Figure 1f ). To confirm the phenotype was cell intrinsic, secondary transplantation was performed. Limiting dilution determined that secondary transfer of 1 × 10 4 primary Dnmt3a KO NICD+ cells was sufficient to transmit T-ALL to 100% of recipients (data not shown). A total of 1 × 10 4 control or Dnmt3a KO NICD+ cells from four primary T-ALLs were transplanted into 4-5 secondary recipients per tumor ( Figure 1g ). Primary Dnmt3a KO NICD+ cells transferred T-ALL rapidly (median survival = 23 days), with a marked reduction in latency and increase in penetrance compared with control NICD+ T-ALL cells (33% of secondary recipients still alive 80 days post transplant, median survival = 56 days).
Dnmt3a KO T-ALL is characterized by DNA hypomethylation at enhancers
To understand how altered DNA methylation might contribute to the pathogenesis, DNA methylation profiles were generated for control and Dnmt3a KO NICD+ T-ALL blasts from moribund mice 
- using enhanced reduced representation bisulfite sequencing (eRRBS). DNA methylation changes were grouped into differentially methylated regions (DMRs), defined as 100 bp regions containing at least three CpGs with a DNA methylation difference of 425% in the same direction (Supplementary Table 1 ). Hierarchical clustering by DNA methylation showed that T-ALLs clustered based on genotype, and independently of normal CD4 +CD8a+ double-positive (DP) T cells (Figure 2a ). Plotting pairwise differences in DMR methylation level between samples showed there were substantially more hypermethylated DMRs in control T-ALL cells compared with normal DP T cells ( Figure 2b) . Conversely, Dnmt3a KO T-ALLs contained more hypomethylated DMRs in comparison to both normal DP T cells and control T-ALL ( Figure 2b ). For genes with DMRs in T-ALL samples compared with DP T cells, Dnmt3a KO samples were consistently hypomethylated compared with control T-ALL in all genomic contexts ( Figure 2c) . Surprisingly, some elements such as promoters showed some gains in DNA methylation in Dnmt3a KO T-ALLs compared with normal DP T cells (Figure 2c Dnmt3a is a T-cell tumor suppressor Dnmt3aKO NICD+ T-ALL exhibits a gene expression profile resembling ETP-ALL RNA-seq gene expression signatures were generated for the same samples used for DNA methylation profiling. There were actually relatively few statistically significant differences between control and Dnmt3a KO blasts (false-discovery rate o0.05, fold-change 42.0-fold), with 283 and 97 genes upregulated and downregulated, respectively, in Dnmt3a KO T-ALL (Supplementary Table 2 ). Gene ontology analysis showed that the genesets downregulated in Dnmt3a KO T-ALLs were predominantly associated with positive regulation of apoptosis and programmed cell death ( Figure 3a) . Conversely, the genesets upregulated in Dnmt3a KO T-ALLs were associated with myeloid cell function and immune/inflammatory response, including genes characteristic of myeloid cells such as Elane, Mpo, Ctsg, Csf2rb and Gfi1b (Figure 3b ). Expression of myeloid genes in T-ALL is characteristic of the ETP-ALL subtype. ETP-ALL comprises up to 15% of adult T-ALL cases, and is associated with a high risk of treatment failure. 23, 24 Genetically, ETP-ALL is distinguished by a high prevalence of DNMT3A mutations. 25 To determine the impact of DNA methylation changes on gene expression, promoter DNA methylation levels of the differentially expressed genes were examined. Similar to our previous studies, 16, 19 gene expression changes between control and Dnmt3a KO T-ALL were not associated with consistent DNA methylation differences (Figure 3c ).
A stem cell origin for Dnmt3a loss-of-function Notch1 gain-offunction T-ALL Given the gene expression similarities between Dnmt3a KO T-ALL and human ETP-ALL, perhaps the shorter latency to T-ALL in a Dnmt3a KO background is predicated more by the developmental context of the leukemia-initiating cells rather than DNA methylation changes. How Dnmt3a inactivation influences the T-ALL cell-of-origin was examined using genetic mouse models permitting induction of oncogenic mutations at different stages of T-cell development. Dnmt3a fl/fl mice were crossed to Rosa26 NICD mice, in which mouse NICD (amino acids 1749-2293) followed by IRES-GFP is knocked into the Rosa26 locus, 26 preceded by a floxed STOP cassette. Inactivation of Dnmt3a and activation of NICD occurs simultaneously in Rosa26 NICD/+ ;Dnmt3a fl/fl mice upon Cre activation. We crossed these mice to Cre drivers expressed in different hematopoietic compartments-Mx1-Cre (HSCs and all hematopoietic cells after pIpC), Lck-Cre (ETPs and thymic progenitors) and CD8a-Cre (mature T cells). Expression specificity was confirmed by crossing Cre drivers to Rosa26 EYFP mice, which express EYFP after Cre-excision of a floxed STOP cassette (Figure 4a ). Treatment of Mx1-Cre:Rosa26 NICD/+ ;Dnmt3a fl/fl and Mx1-CRE: Rosa26 NICD/+ (control) mice with pIpC produced to an off-target hyperinflammatory response with infiltration of mixed immune cells into the skin. To avoid this, we transplanted 1 × 10 6 liver cells from individual P 0 mice into 2-4 recipients per donor. The Cre's were not expressed in the P 0 donor cells, which ensured that donor-derived T-cell development occurred only in the recipient mice (Mx1-Cre expression was induced 4 weeks post transplant by pIpC). No mice transplanted with CD8a-Cre:Rosa26 NICD/+ cells with or without Dnmt3a generated T-ALL (Figure 4b ). Only 1/9 mice transplanted with Lck-Cre:Rosa26 NICD/+ ;Dnmt3a fl/fl or Lck-Cre: Rosa26 NICD/+ cells developed T-ALL (Figure 4c ). Transplantation of P 0 Mx1-Cre:Rosa26 NICD/+ cells generated robust T-ALL, which again was accelerated with loss of Dnmt3a (Figure 4d ). This suggests that T-ALL mutations must occur in a cell more primitive than ETPs for development of this leukemia. In total, 2/10 mice transplanted with Mx1-Cre:Rosa26 NICD/+ cells were still alive after 1 year. Analysis of survivors showed that GFP+ cells could be detected in most hematopoietic compartments, but were conspicuously absent in DN2 thymic progenitors (Figure 4e ). The stem cell origin of this T-ALL was further highlighted by (Figure 4f ). Analysis of surviving mice after 1 year showed that surprisingly, robust chimerism of GFP+ cells could be detected in many hematopoietic cell compartments without T-ALL transformation. However, we noted a striking trend in that there was complete absence of GFP+ cells from both genotypes in the DN2 cell compartment (Figure 4g ).
Loss of Dnmt3a causes developmental arrest of thymic progenitors
The T-ALL results suggested that Dnmt3a loss-of-function might have context-specific effects for T-cell progenitors that influence the leukemic cell-of-origin. To determine the consequences of loss of Dnmt3a for T-cell progenitor development, we performed serial HSC transplantation of 200 pIpC-treated control (Mx1-Cre: Dnmt3a +/+ ) or Dnmt3a KO HSCs (Figure 5a ), and analyzed T-cell development in secondary recipients 18 weeks post transplant. As in previous studies, 16 floxing efficiency of Dnmt3a alleles in the HSCs used for secondary transplant was almost 100% (data not shown). Thymus analysis (Figure 5b) showed that a number of mice transplanted with Dnmt3a KO HSCs showed a significant accumulation of Dnmt3a KO DN2 thymic progenitors (Figure 5c ). However, this phenotype was not fully penetrant with a more than fivefold expansion of donor-derived DN2 cells present in only 38% (9/24) of secondary recipient mice transplanted with Dnmt3a KO HSCs (and was not observed in any of the primary recipients), suggesting some type of selection event or epigenetic stochasticity in those particular mice. This suggests Dnmt3a may be required for normal thymocyte progenitor maturation, even if peripheral blood output is maintained by the cells that do progress through DN2 (Figure 5d ). Dnmt3a is most highly expressed in DN2 thymic progenitors (Figure 5e ), implicating a unique requirement for Dnmt3a activity at this developmental stage.
Dnmt3a KO DN2 thymic progenitors are less apoptotic Apoptosis is a critical and highly regulated process in T-cell development necessary for elimination of autoreactive thymus progenitors during negative selection. 27, 28 PI (propidium iodide) staining (Figure 6a ) showed a significant reduction of PI+ (nonviable) Dnmt3a KO ETP and DN2 cells in the thymus of secondary transplant recipients (Figure 6b ). There was an inverse correlation between the degree of expansion of the Dnmt3a KO DN2 population and the proportion of PI+ cells (Figure 6c ). Independent AnnexinV staining (Figure 6d ) confirmed a lower proportion of apoptotic cells in the Dnmt3a KO DN2 population (Figure 6e ).
Reduced apoptosis of Dnmt3a KO thymic progenitors was not owing to defective TCR rearrangement (Figure 6f ), or owing to aberrant function of Dnmt3b in the absence of Dnmt3a. Although Dnmt3b knockdown in control in vitro-derived DN2 cells increased apoptosis, this effect was abrogated without Dnmt3a (Figure 6g ). Cumulatively, these data suggest that Dnmt3a KO DN2 progenitors accumulate owing to reduced apoptosis.
Nr4a1 is downregulated in Dnmt3a KO DN2 thymic progenitors To investigate molecular mechanisms underlying the developmental arrest of Dnmt3a KO DN2 thymocytes, microarray gene expression profiling was performed. Despite some robust phenotypic differences, there was a high transcriptional similarity between control and Dnmt3a KO DN2 cells ( Supplementary Table 3 ), with only 180 transcripts differentially expressed (ANOVA P-value Dnmt3a is a T-cell tumor suppressor o0.05, fold-change 41.50-fold). We curated the lists to identify potential gene expression differences that might explain the lower apoptotic index of Dnmt3a KO DN2 cells. In microarray results, the orphan nuclear receptor Nr4a1 (also called Nur77) was 2.3-fold downregulated in Dnmt3a KO DN2 cells. This observation was more significant in an extended targeted analysis, which also showed Nr4a1 downregulation in Dnmt3a KO ETPs (Figure 7a ). Dnmt3b was not aberrantly expressed in Dnmt3a KO DN2 cells (Figure 7b inhibition of Dnmt3b in a Dnmt3a KO background did not alter Nr4a1 levels in in vitro-derived DN2 cells (Figure 7c ).
Nr4a1 acts in the apoptotic process during negative selection of T-cell progenitors. 27, 28 In autoreactive T cells, Nr4a1 undergoes phosphorylation-dependent export from the nucleus to the mitochondria, where it conformationally alters Bcl-2 to promote apoptosis. [29] [30] [31] Thus, decreased Nr4a1 expression in Dnmt3a KO DN2 cells could be responsible for the reduced apoptosis. To investigate if Nr4a1 ablation phenocopies Dnmt3a inactivation in T-cell progenitors, thymus analysis of Nr4a1 knockout (Nr4a1 KO ) mice 32 was performed (Figure 7d ). Adult Nr4a1 KO mice showed an expansion of DN2s (Figure 7e ), which were less apoptotic (Figure 7f ), reminiscent of Dnmt3a KO DN2 cells.
We used a retroviral rescue model to determine whether increasing Nr4a1 in Dnmt3a KO thymic progenitors could restore apoptotic competence. To specifically investigate the function of Nr4a1 at the DN2 stage, we generated an inducible retrovirus in which the tetracycline trans-activator protein (rtTA3 = Tet-ON) is constitutively expressed with bicistronic expression of Venus fluorescent protein, and on the same plasmid Nr4a1 expression is under the regulation of a tetracycline-responsive promoter element linked to mCherry expression via a 2A peptide (TtRMPVIR-Nr4a1, control empty vector = TtRMPVIR; Figure 7g ). We transduced HSCs and allowed them to develop on OP9-DL1 stroma 33 for 13 days, then added 2.5 ng/ml doxycycline (a dose titrated to induce a twofold increase in Nr4a1 expression; Figure 7h ) and evaluated apoptosis 2 days later (Figure 7i ). In the absence of doxycycline, there was no difference in AnnexinV+ staining in DN2 cells carrying the control or Nr4a1-expressing vector between the control and Dnmt3a KO genotypes. Although induction of Nr4a1 did induce a significant increase in the proportion of AnnexinV+ control DN2 cells, the effect was much more robust in a Dnmt3a KO background (Figure 7j ).
Nr4a1 downregulation is a downstream effector of Dnmt3a loss-of-function in T-ALL
We examined the function of Nr4a1 in Dnmt3a KO T-ALL leukemogenesis. Nr4a1 expression levels were reduced in T-ALLs lacking Dnmt3a (Supplementary Table 2 ). Retroviral expression of NICD in Nr4a1 KO bone marrow progenitors phenocopied the Dnmt3a KO shorter latency to T-ALL ( Figure 8a ). Furthermore, retroviral rescue of Dnmt3a KO primary T-ALL with ectopic Nr4a1 extended survival over control empty vector transduced cells in secondary recipients to a similar extent as rescue with Dnmt3a (Figure 8b) . To determine whether NR4A1 may be a therapeutic target in DNMT3A-mutant T-ALL, we created stable P12-Ichikawa T-ALL cell lines (NOTCH1 mutation) with reduced DNMT3A function by shRNA knockdown. A total of 4/5 shRNAs tested substantially decreased DNMT3A protein expression, and NR4A1 was also reduced in these cells (Figure 8c ). These cells were then treated with Cytosporone B (CsnB), a natural agonist of NR4A1. 34 We determined the IC 50 of CsnB for control P12 to be 0.04 mM. At this dose, P12 cells carrying DNMT3A shRNAs showed retarded growth (Figure 8d ). The same dose of CsnB induced a stronger upregulation of NR4A1 in DNMT3A-shRNA cell lines (Figure 8e ) and increased apoptosis (Figure 8f ), suggesting that DNMT3A loss-of-function makes the cells more sensitive to increased NR4A1 levels. As a mechanism leading to downregulation of Nr4a1 in Dnmt3a loss-of-function cells, we could not identify DNA methylation differences at the Nr4a1 locus in Dnmt3a KO T-ALL cells (Figure 8g ). But DNMT3A binding was enriched over genome background levels at the NR4A1 promoter in control P12 cells (Figure 8h ), suggesting DNMT3A may recruiting transcriptional activating factors to this locus in T cells.
DISCUSSION
In addition crucial roles for Dnmt3a in HSC differentiation 16, 19 and myeloid tumor suppression, 21, 35 the studies presented here establish important functions for Dnmt3a in T-cell development and evolving T-ALL. Although activating NOTCH1 mutations are the major genetic lesion in T-ALL, 7 little progress has been made into developing targeted therapies for these patients, likely owing to the context of how co-operating mutations shape the leukemia biology. We show in mouse models that Dnmt3a loss-of-function co-operates with Notch1 gain-of-function in driving an aggressive T-ALL. Our results suggest for Dnmt3a KO NICD+ T-ALL, the mutations must be acquired in a cell more primitive than ETPs. However, the observation that leukemia-free mice completely lacked GFP+ cells in the DN2 cell compartment suggests there is something unique about this developmental stage that is required for T-cell transformation. These data support a model whereby oncogenic mutations are acquired in a HSC, which allows dissemination throughout hematopoietic progeny. The HSCs may not necessarily be pathogenic themselves, but merely a vessel to acquire, maintain and propagate the mutations. The mutations may only be transformative when they are passed to a more committed progenitor cell with the right combination of developmental context, epigenetic environment and proliferative capacity.
The mutational spectrum of DNMT3A is markedly different in T-ALL than in myeloid malignancies such as acute myeloid leukemia (AML). Although virtually all DNMT3A mutations in AML are heterozygous, 9, 10 T-ALL patients typically harbor homozygous or compound heterozygous DNMT3A mutations, 11, 14, 15 and there is less prevalence of the 'hotspot' DNMT3A R882H dominantnegative variant. 36, 37 Similarly, Dnmt3a-null mice are predisposed to T-ALL when combined with a Flt3 ITD transgene, whereas Dnmt3a-heterozygous mice predominantly develop AML with the same Flt3 ITD allele. 22 This clearly suggests some dose dependence of DNMT3A levels for the lineage of leukemia generated, with 0% DNMT3A activity preferential for T-lineage disease and 50-70% DNMT3A activity predisposing for myeloid neoplasia. In AML, heterozygous non-R882 DNMT3A-mutant AML generally leads to loss-of-function alleles (one wild-type allele plus one loss-of-function allele = 50% wild-type DNMT3A activity), whereas the DNMT3A R882 dominant-negative retains 20% DNA methylation activity of the wild-type protein (one wild-type allele plus one loss-of-function allele = 70% wild-type DNMT3A activity). The functional consequences of the different DNA methylation activity may make lineage-committed more progenitors more susceptible to transformation depending on the nature of the upstream DNMT3A mutation acquired in a HSC. [38] [39] [40] We demonstrate that Dnmt3a KO -derived DN2 progenitors accumulate in the thymus and have reduced apoptosis, partially owing to downregulation of Nr4a1. This mirrors what happens to HSCs lacking Dnmt3a in the bone marrow-expansion of a functionally-defective progenitor cell population. We show mouse and human T cells lacking Dnmt3a are sensitive to increases in Nr4a1 levels. Investigation into more specific NR4A1 agonists as a therapy for DNMT3A-mutant T-ALL warrants further study as there is no established standard of care for patients with relapsed or primary refractory T-ALL, and prognosis remain dismal with a median survival of 5 months. 41 The search for molecular drug targets based on a patient's genetic profile is necessary to improve outcomes. Results from the studies presented here highlight novel therapeutic vulnerabilities of T-ALL driven by distinct combinations of mutations, and are necessary for the development of targeted therapies for this high-risk patient population. the NIH. This work was supported by grants (to GAC) from Alex's Lemonade Stand Foundation, the Children's Discovery Institute (MC-II-2013-286), the American Society of Hematology, and the Sidney Kimmel Foundation. WCW was supported by NIH T32HL008088. HC was supported by an American Society of Hematology scholar award. JN was supported in part by an Alex's Lemonade Stand Foundation POST award. CM was supported in part by NIH T32HL008088, and NIH DK111058-01. ELO was supported by NIH 5T32CA113275-10.
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